Lotus Pharmaceutical Co., Ltd. · TWSE:1795
Lotus Pharmaceutical — H1 2025 Earnings Presentation
17 slides from Lotus Pharmaceutical's earnings presentation, Aug 15, 2025
Slide 1: Lotus Pharmaceutical 1H 25 Financial Results
Lotus Pharmaceutical 1H 25 Financial Results 15 Aug 2025
Slide 2: Safe Harbor Statement
INTRODUCTION 2 Safe Harbor Statement Except for historical information contained herein, the matters set forth in this presentation are forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially. These forward looking statements are no
Slide 3: Agenda
3 Agenda 1. 1H 25 BUSINESS HIGHLIGHTS 2. 1H 25 FINANCIAL RESULTS 3. LOTUS BUSINESS UPDATE
Slide 4: Business Highlights
01 BUSINESS HIGHLIGHTS
Slide 5: 1H 25 Results and Business Highlights
1H 25 RESULTS AND BUSINESS HIGHLIGHTS 5 Resilient Performance in a dynamic environment New 1H Record Revenue TWD9,477mn (+6% YoY) and EBITDA TWD4,143mn (+8% YoY) • Revenue driven by lenalidomide in U.S (+17% YoY) together with a strong performance in Southeast Asia (+176% YoY) • Gross margin of 60%
Slide 6: YTD Pipeline Updates
6 YTD PIPELINE UPDATES Key Licensing Key Filings Key Approvals Key Launches Agreements • Voclosporin (US) • Adcirca(TW) - the first and • Alpha Choay (Vietnam) • Serplulimab(Anti-PD-1 mAb), only class I ERA therapy an orphan drug of small cell • Ruxolitinib IR (EU) • Darbepoetin Alfa (KR) lung cance
Slide 7: YTD Pipeline Summary - R&D and BD
7 YTD PIPELINE SUMMARY - R&D and BD R&D Pipelines - 31 BD Pipelines – 54 Oncology & Immunology 18 23 Primary Care & Lifestyle* 6 18 Central Nervous System 4 4 Cardiovascular - 3 Other Therapeutic Areas 3 6 *Primary Care & Lifestyle: Anti-obesity, Respiratory & Allergy, Endocrinology & Diabetes, Horm
Slide 8: YTD Pipeline Updates - R&D
BUSINESS STRATEGY 8 YTD PIPELINE UPDATES- R&D Product Type in RD Pipelines Pipeline highlights FTF Day1 505b2 Complex Gx 31 projects ongoing 32% o Strong focus on oncology products (18) o Diverse therapeutic areas such as rare diseases, hormonal therapies and CNS products 7% Focused on addressin
Slide 9: YTD Pipeline Updates - BD
BUSINESS STRATEGY 9 YTD PIPELINE UPDATES- BD Product Type in BD Pipelines Pipeline highlights Gx NCE 505b2 Biosimilars Tail-end big pharma brand Co-development 54 High-value, branded innovative products o 6 are signed and the rest in various 33% negotiation stages o 23 Oncology and immunology prod
Slide 10: Financial Information
02 FINANCIAL INFORMATION
Slide 11: 1H 25 Financial Results
11 1H 25 Financial Results (in NTD millions, except for EPS) Key Financials 1H 25 Performance 1H 25 1H 24 YoY Consolidated Revenue 9,477 8,941 +6.0% Cost of Goods (3,768) (3,759) +0.3% • Revenue +6.0% YoY driven by lenalidomide US sales and Gross Profit 5,708 5,182 +10.1% robust growth of SEA market
Slide 12: 1H Revenue +6% YoY Driven by US (Lena) and SEA
12 1H 25 Revenue +6% YoY Driven by US (Lena) and SEA +6% YoY NT$9,477mn 168 NT$8,941mn 37 535 -180 38 -62 z z +12% YoY -0% YoY 1H 24 KR TW SEA RoA US RoW 1H 25
Slide 13: Diversification Across Therapies and Markets
13 Diversification Across Therapies and Markets Diversified Portfolio Revenue Breakdown 1H 25 Revenue Breakdown by TA Primary Care Export 24% & Lifestyle Business 40% 45% Women 45% Central 6% Healthcare US Nervous 16% RoW System 5% Nephrology 5% Export-Gx 2% RoA 9% Branded-Gx SEA Asian Branded TW 29
Slide 14: Strong Capital Structure
14 Strong Capital Structure LTM EBITDA* (NT$mn) NET DEBT/LTM EBITDA* (x) LTM EBITDA Margin(%) 8,204 43 37 1.20 6,284 0.89 2Q 24 2Q 25 2Q 24 2Q 25 2Q 24 2Q 25 *EBITDA =EBIT + Depreciation + Amortization + Impairment + Shared Based Payment
Slide 15: Business Outlook
a Y ‘: : : 03 BUSINESS OUTLOOK
Slide 16: 2025 Business on track, FX as main uncertainty
16 2025 Business on track, FX as main uncertainty Business on Track for 2025 Asian markets tracking well, in particular with successful integration of Teva in Thailand and smooth takeover of Alpha Choay in Vietnam Export markets to see peak lenalidomide sales in Q4 in 2025, Suboxone competitor’s sup
Slide 17: An international pharmaceutical company with global presence
An international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines https://www.lotuspharm.com.tw/ +886 2 2700 5908 [email protected] in www.linkedin.com/company/lotus-pharmaceutica